Follow Phio Pharmaceuticals Corp.. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
5 Stories in coverage 0 Programs 0 Registered trials Nov 3 Latest story
Timeline 5 Pipeline 0 Trials 0
All5 Trials and readouts1 Filings and people5
Details
Headquarters King Of Prussia, PA Incorporated Delaware Industry Pharmaceutical Preparations Formerly RXi Pharmaceuticals Corp (to 2018) Also known as PHIO, RXi Pharmaceuticals Corp How the company describes itself Phio Pharmaceuticals is a clinical-stage company developing INTASYL, a siRNA technology that silences PD-1 to enhance immune cell killing of cancer cells. Its lead program, PH-762, is in Phase 1b trials for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. source